Amphastar Pharmaceuticals (AMPH) Total Current Liabilities (2013 - 2026)
Amphastar Pharmaceuticals (AMPH) posted quarterly Total Current Liabilities of $164.5 million for Q1 2026, down 17.37% year-over-year from $199.1 million in Q1 2025, and up 4.0% quarter-over-quarter from $158.2 million in Q4 2025.
Amphastar Pharmaceuticals (AMPH) Total Current Liabilities (2013 - 2026) Analysis & Trends
Amphastar Pharmaceuticals' Total Current Liabilities history runs 14 years deep, the most recent figure standing at $164.5 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 17.37% year-over-year to $164.5 million; the TTM figure through Mar 2026 stood at $164.5 million (down 17.37% YoY), while the FY2025 annual figure was $158.2 million, down 8.98% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $164.5 million, up from $158.2 million in the prior quarter.
- The five-year high for Total Current Liabilities was $258.0 million in Q3 2023, with the low at $94.9 million in Q4 2022.
- The 5-year median for Total Current Liabilities is $164.5 million (2026), against an average of $169.6 million.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities soared 152.43% in 2023, then tumbled 45.49% in 2024.
- Amphastar Pharmaceuticals' Total Current Liabilities stood at $94.9 million in 2022, then jumped by 137.62% to $225.4 million in 2023, then decreased by 22.91% to $173.8 million in 2024, then dropped by 8.98% to $158.2 million in 2025, then rose by 4.0% to $164.5 million in 2026.
- Business Quant data shows AMPH's Total Current Liabilities at $164.5 million in Q1 2026, $158.2 million in Q4 2025, and $205.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | 1.79 Bn |
| 10 | Amphastar Pharmaceuticals | 942.71 Mn | 652.59 Mn | 93.47 Mn | 263.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 263.21 Mn |
| Mar 31, 2026 | 164.48 Mn |
| Dec 31, 2025 | 158.16 Mn |
| Sep 30, 2025 | 205.23 Mn |
| Jun 30, 2025 | 176.41 Mn |
| Mar 31, 2025 | 199.05 Mn |
| Dec 31, 2024 | 173.76 Mn |
| Sep 30, 2024 | 159.01 Mn |
| Jun 30, 2024 | 136.97 Mn |
| Mar 31, 2024 | 255.17 Mn |
| Dec 31, 2023 | 225.41 Mn |
| Sep 30, 2023 | 257.96 Mn |
| Jun 30, 2023 | 251.29 Mn |
| Mar 31, 2023 | 105.64 Mn |
| Dec 31, 2022 | 94.86 Mn |
| Sep 30, 2022 | 102.19 Mn |
| Jun 30, 2022 | 103.63 Mn |
| Mar 31, 2022 | 114.36 Mn |
| Dec 31, 2021 | 103.81 Mn |
| Sep 30, 2021 | 97.99 Mn |